Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand. - 2Photos of amputees in Gaza, struggling to survive after losing limbs to Israeli airstrikes
- 3Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- 4Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
- 5The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- Remote Work Survival manual: Helping Efficiency at Home
- Find Your Internal Culinary expert: Cooking Strategies and Recipes
- Select Your Go-To Bluetooth Earphones
- Underestimated Metropolitan Experience Urban communities On the planet
- 6 Financial plan 3D Printers with the Best Worth
- Favored Organic product for Seniors' Prosperity: Make Your Determination
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- 6 Web-based Staple Help You Can Trust
- Japanese H3 rocket fails during launch of navigation satellite (video)
